Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model

Journal of Surgical Research

Volumn 108, Issue 1, 2002, Pages 107-111

  Ghiselli, Roberto ^a   Giacometti, Andrea ^b   Cirioni, Oscar ^b   Mocchegiani, Federico ^a   Viticchi, Claudio ^a   Scalise, Giorgio ^b   Saba, Vittorio ^a  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM DERIVATIVE; BUFORIN II; COLISTIN; ENDOTOXIN; IMIPENEM; PEPTIDE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CECUM; CONTROLLED STUDY; DRUG EFFICACY; LETHALITY; MALE; MORTALITY; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; RAT;

EID: 0036441278     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2002.6518     Document Type: Article

References (29)

1. Fabian, T. C. Prevention of infections following penetrating abdominal trauma. Am. J. Surg. 165: S14, 1993.
2. Dupont, H., Carbon, C., Carlet, J. for The Severe Generalized Peritonitis Study Group. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminogly-cosides in treatment of severe generalized peritonitis: A multi-center randomized controlled trial. Antimicrob. Agents Chemother. 44: 2028, 2000.
3. Johnson, C. C., Baldessare, J., and Levison, M. E. Peritonitis: Update on pathophysiology, clinical manifestations, and management. Clin. Infect. Dis. 24: 1035, 1997.
4. Montravers, P., Andremont, A., Massias, L., and Carbon, C. Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J. Infect. Dis. 169: 821, 1993.
5. Saklayen, M. G. CAPD peritonitis: Incidence, pathogens, diagnosis, and management. Med. Clin. N. Am. 74: 997, 1990.
6. Montravers, P., Gauzit, R., Muller, C., Marmuse, J. P., Fichelle, A., and Desmonts, J. M. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intrabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. 23: 486, 1996.
7. Jaccard, C., Troillet, N., Harbarth, S., Zanetti, G., Aymon, D., Schneider, R., Chiolero, R., Ricou, B., Huber, O., Ambrosetti, P., Praz, G., Lew, D., Bille, J., Glauser, M. P., and Cometta, A. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 42: 2966, 1998.
8. Perdue, P. W., Kazarian, K. K., Nevola, J., Law, W. R., and Williams, T. The use of local and systemic antibiotics in rat fecal peritonitis. J. Surg. Res. 57: 360, 1994.
9. Barekzi, N. A., Poelstra, K. A., Felts, A. G., Rojas, I. A., Slunt, J. B., and Grainger, D. W. Efficacy of locally delivered poly-clonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Antimicrob. Agents Chemother. 43: 1609, 1999.
10. Colardyn, F., and Faulkner, K. L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J. Antimicrob. Chemother. 38: 523, 1996.
11. Neu, H. C. The crisis in antibiotic resistance. Science 257: 1064, 1992.
12. Gough, M., Hancock, R. E. W., and Kelly, N. M. Antiendotoxin activity of cationic peptide antimicrobial antibiotics. Infect. Immun. 64: 4922, 1996.
13. Iwagaki, A., Porro, M., and Pollack, M. Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infect. Immun. 68: 1655, 2000.
14. Hancock, R. E. W., and Scott, M. G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. USA 97: 856, 2000.
15. Giacometti, A., Cirioni, O., Ghiselli, R., Viticchi, C., Mocchegiani, F., Riva, A., Saba, V., and Scalise, G. Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Crit. Care Med. 29: 1666, 2001.
16. Cannon, M. A. Family of wound healers. Nature 328: 478, 1987.
17. Bevins, C. L., and Zasloff, M. Peptides from frog skin. Annu. Rev. Biochem. 59: 395, 1990.
18. Boman, H. G., and Hultmark, D. Cell-free immunity in insects. Annu. Rev. Microbiol. 41: 103, 1987.
19. Refsum, S. E., Halliday, M. I., Campbell, G., McCaigue, M., Rowlands, B. J., and Boston, V. E. Modulation of TNF alpha and IL-6 in a peritonitis model usind pentoxifylline. J. Pediatr. Surg. 31: 928, 1996.
20. Wherry, J., Wenzel, R., Abraham, E., Allred, R., Balk, R., Bone, R., Levy, H., Nasraway, S., Perl, T., Silverman, H., Winderink, R., and the TNF Mab Study Group. A controlled randomized double blind clinical trial of monoclonal antibody to tumor necrosis factor (TNF MAb) in patients with sepsis syndrome. Chest 104: S3, 1993.
21. Ziegler, E. J., Fisher, C. J., Jr., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., Allen, I. E., Berger, H. J., Knatterud, G. L., LoBuglio, A. F., Smith, C. R., and the HA-1A Sepsis Study Group. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endo-toxin: A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324: 429, 1999.
22. Vaara, M., and Porro, M. Group of peptides that act synergistically with hydrophobic antibiotics against Gram-negative enteric bacteria. Antimicrob. Agents Chemother. 40: 1801, 1996.
23. Park, C. B., Yi, K. S., Matsuzaki, K., Kim, M. S., and Kim, S. C. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: The proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. USA 97: 8245, 2000.
24. Prins, J. M., Kuijper, E. J., Mevissen, M. L. C. M., Speelman, P., and van Deventer, S. J. H. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: Influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect. Immun. 63: 2236, 1995.
25. Neu, H. C. Relation of structural properties of beta-lactam antibiotics to antibacterial activity. Am. J. Med. 79(Suppl 2A): 2, 1985.
26. Echtenacher, B., Weigl, K., Lehn, N., and Mannel, D. N. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect. Immun. 69: 3550, 2001.
27. Hancock, R. E. W. Peptides antibiotics. Lancet 349: 418, 1997.
28. Hancock, R. E. W., and Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother. 43: 1317, 1999.
29. Zasloff, M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 84: 5449, 1987.